{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "ccf2c016-5445-42e7-9f0f-5ce3cfbe0da8",
   "metadata": {},
   "source": [
    "# Mistake analysis\n",
    "This notebook gives a quick look into the predications the model makes that are wrong according to the reference evaluation data. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "30446cb9-44dc-4b1f-8afd-423f530500f6",
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import (\n",
    "    T5Tokenizer,\n",
    "    AutoTokenizer,\n",
    "    T5ForConditionalGeneration,\n",
    "    Seq2SeqTrainingArguments,\n",
    "    Seq2SeqTrainer,\n",
    "    DataCollatorForSeq2Seq\n",
    ")\n",
    "import torch\n",
    "from datasets import load_dataset, concatenate_datasets\n",
    "from wasabi import msg\n",
    "import yaml\n",
    "import re\n",
    "import pandas as pd\n",
    "from pathlib import Path\n",
    "from os.path import abspath\n",
    "from tqdm import tqdm\n",
    "from typing import Set, Dict, Tuple, Union\n",
    "from helper_functions import *"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "41b36a1f-736c-4f00-9a9a-de0e44b7c052",
   "metadata": {},
   "source": [
    "## Setting home directory"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "aea61d60-6ae8-4f91-889a-8329d5d1ea68",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4mℹ Home directory: /home/lgrootde/Generative-re-tests\u001b[0m\n",
      "\u001b[38;5;4mℹ Selected config:\n",
      "/home/lgrootde/Generative-re-tests/config/config_T5-3b_cdr.yaml\u001b[0m\n",
      "\u001b[38;5;4mℹ Selected model:\n",
      "/home/lgrootde/data/generative_re_model_storage_azure/47/checkpoints/checkpoint-100\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "home_dir = Path(abspath(\"\")).parent\n",
    "config_path = home_dir.joinpath(\"config/config_T5-3b_cdr.yaml\")\n",
    "trained_model_path = home_dir.parent.joinpath(\"data/generative_re_model_storage_azure/47/checkpoints/checkpoint-100\")\n",
    "predictions_dataset_dir = home_dir.joinpath(\"data/evaluate_trained_model\")\n",
    "\n",
    "msg.info(f\"Home directory: {home_dir}\")\n",
    "msg.info(f\"Selected config: {config_path}\")\n",
    "msg.info(f\"Selected model: {trained_model_path}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "473b11ad-6e32-4421-aad2-2c35a5fcb7af",
   "metadata": {},
   "source": [
    "## Load Config & Dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "5ee923f6-dca8-4afa-be9a-16bb513a3fe0",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the config\n",
    "with open(config_path) as f:\n",
    "    config = yaml.load(f, Loader=yaml.FullLoader)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "13ad9288-daf4-4801-bcbe-448e71ad114c",
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset = load_dataset(\n",
    "        config['dataset_vars']['type'], \n",
    "        data_dir=home_dir.joinpath(config['dataset_vars']['dir']),\n",
    "        column_names=config['dataset_vars']['column_names']\n",
    "        )\n",
    "\n",
    "dataset_eval = concatenate_datasets([dataset[split].select(range(1,501)) for split in config[\"splits_for_validation\"]]) "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2616f3ae-11a9-4ae2-a192-9e47b9d1fe6e",
   "metadata": {},
   "source": [
    "## Load trained model and tokenizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "a0b48f98-164f-44e7-b41e-2ff803848be8",
   "metadata": {},
   "outputs": [],
   "source": [
    "use_model = False"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "aed39acd-7fa3-4c1a-81f5-9a09398eff39",
   "metadata": {},
   "outputs": [],
   "source": [
    "if use_model:\n",
    "    model_name = config['model_name']\n",
    "    device_map = {\"\": 0}\n",
    "    \n",
    "    # Load tokenizer\n",
    "    tokenizer = AutoTokenizer.from_pretrained(model_name, trust_remote_code=True, legacy=False)\n",
    "    \n",
    "    # Load model after training\n",
    "    model = T5ForConditionalGeneration.from_pretrained(\n",
    "        trained_model_path,\n",
    "        device_map=device_map,\n",
    "        local_files_only=True\n",
    "    )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "49ca2f40-340e-4e6b-8bdf-512aebc57afb",
   "metadata": {},
   "source": [
    "## Run model over evaluation dataset \n",
    "And note where the model makes mistakes and where the model prediction match the reference."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "697f30ab-d1ae-4fdf-b448-09a9dd17cae1",
   "metadata": {},
   "outputs": [],
   "source": [
    "if use_model:\n",
    "    # run model over dataset\n",
    "    data = {\n",
    "        \"input\":[],\n",
    "        \"expected output\":[],\n",
    "        \"predicted output\":[],\n",
    "        \"match\":[]\n",
    "    }\n",
    "    \n",
    "    for row in tqdm(dataset_eval):\n",
    "        # Generate prediction\n",
    "        input_ids = tokenizer(row['input'], return_tensors=\"pt\").input_ids.to('cuda') \n",
    "        output = model.generate(input_ids, max_new_tokens=config[\"generation_max_length\"])\n",
    "        predicted = tokenizer.decode(output[0], skip_special_tokens=True)\n",
    "    \n",
    "        # check for match\n",
    "        if row[\"relations\"].strip() == predicted.strip():\n",
    "            match = True\n",
    "        else:\n",
    "            match = False\n",
    "    \n",
    "        # Save all information\n",
    "        data[\"input\"].append(row[\"input\"])\n",
    "        data[\"expected output\"].append(row[\"relations\"])\n",
    "        data[\"predicted output\"].append(predicted)\n",
    "        data[\"match\"].append(match)\n",
    "        \n",
    "    dataframe = pd.DataFrame.from_dict(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "0bb0a1ed-b90d-43d7-b7a2-b44e792dfb85",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4mℹ dataset name: run47_checkpoint-100_on_cdr_seq2rel_validation.csv\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "# Save dataframe   \n",
    "dataset_name = (\"run\"+\n",
    "                trained_model_path.parts[-3]+\n",
    "                \"_\"+\n",
    "                trained_model_path.parts[-1]+\n",
    "                \"_\"+\n",
    "                \"on\"+\n",
    "                \"_\"+\n",
    "                Path(config['dataset_vars']['dir']).parts[-1]+\n",
    "                \"_\"+\n",
    "                \"_\".join(config[\"splits_for_validation\"])+\n",
    "                \".csv\")\n",
    "    \n",
    "msg.info(f\"dataset name: {dataset_name}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "c1594ae3-9da1-4a77-a5ec-54cca94ed22c",
   "metadata": {},
   "outputs": [],
   "source": [
    "if use_model:\n",
    "    # Save dataframe\n",
    "    dataframe.to_csv(predictions_dataset_dir.joinpath(dataset_name))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c82d2abc-601f-4764-8e73-9519ab2c8eab",
   "metadata": {},
   "source": [
    "## Show data for manual inspection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "363054c7-463f-4db1-87eb-cb31d78630b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load dataset:\n",
    "dataset_path = predictions_dataset_dir.joinpath(dataset_name)\n",
    "dataframe = pd.read_csv(dataset_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "ada96cdf-047f-4f3e-b0d7-664d2a54a0d3",
   "metadata": {},
   "outputs": [],
   "source": [
    "def highlight_entities(input_text: str, rels_expected: Set[Dict], rels_predicted: Set[Dict]) -> str:\n",
    "    # Create a set to store all entity texts for predicted relationships\n",
    "    entity_texts_predicted = set()\n",
    "    \n",
    "    # Extract all entity texts from the predicted relationships data\n",
    "    for rel in rels_predicted:\n",
    "        head_ent_text = rel['head_ent']['text']\n",
    "        if isinstance(head_ent_text, tuple):\n",
    "            for text in head_ent_text:\n",
    "                entity_texts_predicted.add(text)\n",
    "        else:\n",
    "            entity_texts_predicted.add(head_ent_text)\n",
    "        \n",
    "        tail_ent_text = rel['tail_ent']['text']\n",
    "        if isinstance(tail_ent_text, tuple):\n",
    "            for text in tail_ent_text:\n",
    "                entity_texts_predicted.add(text)\n",
    "        else:\n",
    "            entity_texts_predicted.add(tail_ent_text)\n",
    "\n",
    "    # Highlight the entity texts for predicted relationships in the input text with pastel blue color\n",
    "    highlighted_text = input_text\n",
    "    for entity_text in entity_texts_predicted:\n",
    "        highlighted_text = re.sub(r'\\b{}\\b'.format(re.escape(entity_text)),\n",
    "                                  '\\033[48;2;173;216;230;38;2;0;0;0m{}\\033[00m'.format(entity_text),\n",
    "                                  highlighted_text, flags=re.IGNORECASE)\n",
    "    \n",
    "    # Create a set to store all entity texts for expected relationships\n",
    "    entity_texts_expected = set()\n",
    "    \n",
    "    # Extract all entity texts from the expected relationships data\n",
    "    for rel in rels_expected:\n",
    "        head_ent_text = rel['head_ent']['text']\n",
    "        if isinstance(head_ent_text, tuple):\n",
    "            for text in head_ent_text:\n",
    "                entity_texts_expected.add(text)\n",
    "        else:\n",
    "            entity_texts_expected.add(head_ent_text)\n",
    "        \n",
    "        tail_ent_text = rel['tail_ent']['text']\n",
    "        if isinstance(tail_ent_text, tuple):\n",
    "            for text in tail_ent_text:\n",
    "                entity_texts_expected.add(text)\n",
    "        else:\n",
    "            entity_texts_expected.add(tail_ent_text)\n",
    "\n",
    "    \n",
    "\n",
    "    # Highlight the entity texts for expected relationships in the input text with pastel green color\n",
    "    for entity_text in entity_texts_expected:\n",
    "        highlighted_text = re.sub(r'\\b{}\\b'.format(re.escape(entity_text)),\n",
    "                                  '\\033[48;2;144;238;144;38;2;0;0;0m{}\\033[00m'.format(entity_text),\n",
    "                                  highlighted_text, flags=re.IGNORECASE)\n",
    "\n",
    "    return highlighted_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "a058f804-2d34-482f-b22f-5d40cbc8e929",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities of expected output colored \u001b[48;2;144;238;144;38;2;0;0;0mgreen\u001b[00m, of predicted \u001b[48;2;173;216;230;38;2;0;0;0mblue\u001b[00m\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mtricuspid valve regurgitation\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mlithium carbonate\u001b[00m toxicity in a newborn infant. A newborn with massive tricuspid regurgitation, atrial flutter, \u001b[48;2;173;216;230;38;2;0;0;0mcongestive heart failure\u001b[00m, and a high serum lithium level is described. This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. \u001b[48;2;173;216;230;38;2;0;0;0mlithium carbonate\u001b[00m may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes \u001b[48;2;144;238;144;38;2;0;0;0mneurologic depression\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0mcyanosis\u001b[00m, and \u001b[48;2;144;238;144;38;2;0;0;0mcardiac arrhythmia\u001b[00m when consumed prior to delivery.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lithium carbonate @CHEMICAL@ neurologic depression @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cyanosis @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ cardiac arrhythmia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lithium carbonate @CHEMICAL@ tricuspid valve regurgitation @DISEASE@ @CID@ lithium carbonate @CHEMICAL@ congestive heart failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Acute changes of blood \u001b[48;2;144;238;144;38;2;0;0;0mammonia\u001b[00m may predict short-term adverse effects of \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0mvalproic acid\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs. A standardized loading dose of \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours. \u001b[48;2;144;238;144;38;2;0;0;0mammonia\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mnh3\u001b[00m) was higher in patients who, during continuous therapy, complained of \u001b[48;2;173;216;230;38;2;0;0;0mdrowsiness\u001b[00m (7 patients) than in those who were symptom-free (17 patients), although \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m plasma levels were similar in both groups. By measuring \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m-induced changes of blood \u001b[48;2;144;238;144;38;2;0;0;0mnh3\u001b[00m content, it may be possible to identify patients at higher risk of obtundation when \u001b[48;2;173;216;230;38;2;0;0;0mvpa\u001b[00m is given chronically.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "ammonia ; nh3 @CHEMICAL@ drowsiness @DISEASE@ @CID@ valproic acid ; vpa @CHEMICAL@ drowsiness @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "valproic acid ; vpa @CHEMICAL@ drowsiness @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Development of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mcardiac hypertrophy\u001b[00m. The development of \u001b[48;2;173;216;230;38;2;0;0;0mcardiac hypertrophy\u001b[00m was studied in adult female Wistar rats following daily subcutaneous injections of \u001b[48;2;173;216;230;38;2;0;0;0misoproterenol\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m) (0.3 mg/kg body weight). A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content. Heart weight increased 44% after 8 days of treatment with a half time of 3.4 days. Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy. The half time for RNA accumulation was 2.0 days. The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy. Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment. Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy. However, dP/dt in the \u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m-treated hearts was slightly but significantly (P less than 0.05) elevated. These data indicate that the adaptive response to \u001b[48;2;173;216;230;38;2;0;0;0miso\u001b[00m shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA. However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and \u001b[48;2;144;238;144;38;2;0;0;0mhyperplasia\u001b[00m within the heart.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "isoproterenol ; iso @CHEMICAL@ cardiac hypertrophy @DISEASE@ @CID@ isoproterenol ; iso @CHEMICAL@ hyperplasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "isoproterenol ; iso @CHEMICAL@ cardiac hypertrophy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Co-carcinogenic effect of retinyl acetate on \u001b[48;2;173;216;230;38;2;0;0;0mforestomach carcinogenesis\u001b[00m of male F344 rats induced with \u001b[48;2;173;216;230;38;2;0;0;0mbutylated hydroxyanisole\u001b[00m. The potential modifying effect of retinyl acetate (RA) on \u001b[48;2;173;216;230;38;2;0;0;0mbutylated hydroxyanisole\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m)-induced rat \u001b[48;2;173;216;230;38;2;0;0;0mforestomach tumorigenesis\u001b[00m was examined. Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks. In groups given 2% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of \u001b[48;2;144;238;144;38;2;0;0;0mforestomach tumors\u001b[00m (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water. In rats given 1% \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m-induced epithelial hyperplasia. Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration. RA alone did not induce hyperplastic changes in the forestomach. These findings indicate that RA acted as a co-carcinogen in the \u001b[48;2;173;216;230;38;2;0;0;0mbha\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mforestomach carcinogenesis\u001b[00m of the rat.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "butylated hydroxyanisole ; bha @CHEMICAL@ forestomach carcinogenesis ; forestomach tumorigenesis ; forestomach tumors @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "butylated hydroxyanisole ; bha @CHEMICAL@ forestomach carcinogenesis ; forestomach tumorigenesis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Ketanserin pretreatment reverses \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m. Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m produced in rats by the potent short-acting opiate agonist \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m. Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m was assessed by analyzing root-mean-square electromyographic activity. Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m-induced increase in electromyographic activity compared with animals pretreated with saline. Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m produced by \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m. Despite the absence of \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m were motionless, flaccid, and less responsive to external stimuli than were animals receiving \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m alone. Rats that received ketanserin and \u001b[48;2;173;216;230;38;2;0;0;0malfentanil\u001b[00m exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that \u001b[48;2;173;216;230;38;2;0;0;0mmuscle \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m\u001b[00m, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced \u001b[48;2;144;238;144;38;2;0;0;0mrigidity\u001b[00m, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "alfentanil @CHEMICAL@ muscle rigidity ; rigidity @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "alfentanil @CHEMICAL@ muscle rigidity @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mcerebral sinus thrombosis\u001b[00m as a potential hazard of antifibrinolytic treatment in menorrhagia. We describe a 42-year-old woman who developed superior sagittal and \u001b[48;2;173;216;230;38;2;0;0;0mleft transverse sinus thrombosis\u001b[00m associated with prolonged \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-\u001b[48;2;173;216;230;38;2;0;0;0maminocaproic acid\u001b[00m\u001b[00m therapy for menorrhagia. This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss. Although increased risk of thromboembolic disease has been reported during treatment with \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-\u001b[48;2;173;216;230;38;2;0;0;0maminocaproic acid\u001b[00m\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0mcerebral sinus thrombosis\u001b[00m has not been previously described. Careful use of \u001b[48;2;173;216;230;38;2;0;0;0mepsilon-\u001b[48;2;173;216;230;38;2;0;0;0maminocaproic acid\u001b[00m\u001b[00m therapy is recommended.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "epsilon-aminocaproic acid @CHEMICAL@ sagittal sinus thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "epsilon-aminocaproic acid @CHEMICAL@ cerebral sinus thrombosis @DISEASE@ @CID@ aminocaproic acid @CHEMICAL@ superior sagittal and left transverse sinus thrombosis @DISEASE@ @CID@ aminocaproic acid @CHEMICAL@ left transverse sinus thrombosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mhepatic \u001b[48;2;144;238;144;38;2;0;0;0madenomas\u001b[00m\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfocal nodular hyperplasia of the liver\u001b[00m in young women on \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m: case reports. Two cases of hepatic \u001b[48;2;144;238;144;38;2;0;0;0madenoma\u001b[00m and one of \u001b[48;2;144;238;144;38;2;0;0;0mfocal nodular hyperplasia\u001b[00m presumably associated with the use of \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m, are reported. Special reference is made to their clinical presentation, which may be totally asymptomatic. Liver-function tests are of little diagnostic value, but valuable information may be obtained from both liver scanning and hepatic angiography. Histologic differences and clinical similarities between hepatic \u001b[48;2;144;238;144;38;2;0;0;0madenoma\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mfocal nodular hyperplasia of the liver\u001b[00m are discussed.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptives @CHEMICAL@ adenomas ; adenoma @DISEASE@ @CID@ oral contraceptives @CHEMICAL@ focal nodular hyperplasia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives @CHEMICAL@ hepatic adenomas @DISEASE@ @CID@ oral contraceptives @CHEMICAL@ focal nodular hyperplasia of the liver @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Arterial thromboembolism in patients receiving systemic \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy: a complication associated with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m. Arterial thromboembolism is a recognized complication of systemic \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy. Characteristic of the entity is \u001b[48;2;144;238;144;38;2;0;0;0marterial occlusion\u001b[00m by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m therapy, preceded by profound \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m are reviewed. The common factor relating thromboembolism and \u001b[48;2;173;216;230;38;2;0;0;0mthrombocytopenia\u001b[00m is \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced platelet aggregation. Appropriate treatment consists of discontinuation of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, and anticoagulation with sodium warfarin if necessary. Vascular procedures are performed as indicated.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@ heparin @CHEMICAL@ arterial occlusion @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombocytopenia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Serotonin 6 receptor gene is associated with \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m in a Japanese population. BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for \u001b[48;2;144;238;144;38;2;0;0;0mpsychotic disorders\u001b[00m such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of \u001b[48;2;144;238;144;38;2;0;0;0mpsychotic disorders\u001b[00m. The symptoms of \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m)-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m are similar to those of paranoid type schizophrenia. Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m. METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m patients and 337 controls) in the Japanese population. The age and sex of the control subjects did not differ from those of the \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m dependence patients. RESULTS: rs6693503 was associated with \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m patients in the allele/genotype-wise analysis. Moreover, this association remained significant after Bonferroni correction. In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m patients, respectively. CONCLUSION: HTR6 may play an important role in the pathophysiology of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mpsychosis\u001b[00m in the Japanese population.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ psychosis ; psychotic disorders @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ psychosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of increasing intraperitoneal infusion rates on \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m hydrochloride-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m in mice. BACKGROUND: It is not known if there is a relationship between input rate and incidence of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m. This is important, since different controlled release formulations of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m release the active drug at different rates. METHODS: We investigated the effect of varying the intraperitoneal infusion rates of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m HCl 120 mg/kg, a known \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m dose 50 (CD50), on the incidence and severity of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in the Swiss albino mice. A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group). \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min. The number, time of onset, duration and the intensity of the \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m or absence of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m were recorded. RESULTS: The results showed that IP administration of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m HCl 120 mg/kg by bolus injection induced \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in 6 out of 10 mice (60% of convulsing mice) in group 1. Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m HCl 120 mg/kg was associated with a 91% reduced odds of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m at infusion times of 15 to 90 min compared to bolus injection. Further increase in infusion time resulted in further reduction in the odds of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m to 99.8% reduction at 240 min. CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and \u001b[48;2;144;238;144;38;2;0;0;0mconvulsive\u001b[00m dose of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m and the risk of \u001b[48;2;173;216;230;38;2;0;0;0mconvulsions\u001b[00m in a prospective study is novel.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupropion hydrochloride ; bupropion ; bupropion hcl @CHEMICAL@ seizures ; convulsive ; convulsions @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupropion ; bupropion hcl @CHEMICAL@ convulsions ; convulsions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Detailed spectral profile analysis of \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mepileptiform\u001b[00m activity in anesthetized rats. \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m model is a widely used experimental model for \u001b[48;2;173;216;230;38;2;0;0;0mepilepsy\u001b[00m research. In the present study we aimed to portray a detailed spectral analysis of \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mepileptiform\u001b[00m activity in comparison with basal brain activity in anesthetized Wistar rats. Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup. After a short period of basal activity recording, \u001b[48;2;173;216;230;38;2;0;0;0mepileptic focus\u001b[00m was induced by injecting 400IU/2 microl \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-G potassium into the left lateral ventricle while the cortical activity was continuously recorded. Basal activity, latent period and the \u001b[48;2;173;216;230;38;2;0;0;0mpenicillin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mepileptiform\u001b[00m activity periods were then analyzed using both conventional methods and spectral analysis. Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands. Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the \u001b[48;2;173;216;230;38;2;0;0;0mepileptiform\u001b[00m activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and \u001b[48;2;173;216;230;38;2;0;0;0mepileptiform\u001b[00m activity). Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental \u001b[48;2;144;238;144;38;2;0;0;0mepilepsies\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "penicillin-g potassium @CHEMICAL@ epileptiform activity ; epilepsy ; epileptic ; epilepsies @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "penicillin @CHEMICAL@ epileptiform ; epileptic focus @DISEASE@ @CID@ penicillin @CHEMICAL@ epilepsy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m causes alterations in the MAP kinase-related pathways in the brains of mice that display \u001b[48;2;173;216;230;38;2;0;0;0mincreased \u001b[48;2;144;238;144;38;2;0;0;0maggressiveness\u001b[00m\u001b[00m. \u001b[48;2;173;216;230;38;2;0;0;0maggressive behaviors\u001b[00m have been reported in patients who suffer from some \u001b[48;2;144;238;144;38;2;0;0;0mpsychiatric disorders\u001b[00m, and are common in \u001b[48;2;173;216;230;38;2;0;0;0mmethamphetamine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m) abusers. Herein, we report that multiple (but not single) injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m significantly \u001b[48;2;173;216;230;38;2;0;0;0mincreased \u001b[48;2;144;238;144;38;2;0;0;0maggressiveness\u001b[00m\u001b[00m in male CD-1 mice. This increase in \u001b[48;2;144;238;144;38;2;0;0;0maggressiveness\u001b[00m was not secondary to \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m-induced hyperactivity. Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m injections. There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. MEK1 was significantly decreased also after a single injection of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m, but to a much lesser degree than after multiple injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of \u001b[48;2;173;216;230;38;2;0;0;0mmeth\u001b[00m. These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of \u001b[48;2;173;216;230;38;2;0;0;0maggressive behaviors\u001b[00m in mice.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ aggressiveness ; aggressive behaviors ; psychiatric disorders @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "methamphetamine ; meth @CHEMICAL@ increased aggressiveness ; aggressive behaviors @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mlamotrigine\u001b[00m associated with exacerbation or de novo \u001b[48;2;173;216;230;38;2;0;0;0mmyoclonus\u001b[00m in idiopathic generalized epilepsies. Five patients with idiopathic generalized epilepsies (IGE) treated with \u001b[48;2;173;216;230;38;2;0;0;0mlamotrigine\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m) experienced exacerbation or de novo appearance of \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonic jerks\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mmj\u001b[00m). In three patients, \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m exacerbated \u001b[48;2;144;238;144;38;2;0;0;0mmj\u001b[00m in a dose-dependent manner with early aggravation during titration. \u001b[48;2;144;238;144;38;2;0;0;0mmj\u001b[00m disappeared when \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m dose was decreased by 25 to 50%. In two patients, \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m exacerbated \u001b[48;2;144;238;144;38;2;0;0;0mmj\u001b[00m in a delayed but more severe manner, with \u001b[48;2;144;238;144;38;2;0;0;0mmyoclonic status\u001b[00m that only ceased after \u001b[48;2;173;216;230;38;2;0;0;0mltg\u001b[00m withdrawal.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "lamotrigine ; ltg @CHEMICAL@ myoclonus ; myoclonic jerks ; mj ; myoclonic status @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "lamotrigine ; ltg @CHEMICAL@ myoclonus @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "rTMS of supplementary motor area modulates therapy-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m in Parkinson disease. The neural mechanisms and circuitry involved in \u001b[48;2;173;216;230;38;2;0;0;0mlevodopa\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mdyskinesia\u001b[00m are unclear. Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a \u001b[48;2;173;216;230;38;2;0;0;0mdyskinetic state\u001b[00m induced by continuous apomorphine infusion. rTMS at 1 Hz was observed to markedly reduce drug-induced \u001b[48;2;173;216;230;38;2;0;0;0mdyskinesias\u001b[00m, whereas 5-Hz rTMS induced a slight but not significant increase.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinesia ; dyskinetic ; drug-induced dyskinesias @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "levodopa @CHEMICAL@ dyskinesias ; dyskinetic state @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Assessment of the onset and persistence of \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m during procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m. OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring. METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with \u001b[48;2;173;216;230;38;2;0;0;0mpropofol\u001b[00m between December 28, 2002, and October 31, 2003. BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status. At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator. The BIS score at the time the word was read and the patient's ability to repeat the word were recorded. After the procedure, the patient was asked to state all of the words from the list that he or she could recall, and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed. RESULTS: Seventy-five consenting patients were enrolled; one patient was excluded from data analysis for a protocol violation. No serious adverse events were noted during the procedural sedations. The mean (+/-standard deviation) time of data collection was 16.4 minutes (+/-7.1; range 5 to 34 minutes). The mean initial (preprocedure) BIS score was 97.1 (+/-2.3; range 92 to 99). The mean lowest BIS score occurring during these procedural sedations was 66.9 (+/-14.4; range 33 to 91). The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77.1 (95% CI = 74.3 to 80.0). The mean highest BIS score corresponding to the \u001b[48;2;144;238;144;38;2;0;0;0minability to repeat words\u001b[00m was 81.5 (95% CI = 78.1 to 84.8). The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96.7 (+/-2.4; range 84 to 98). The mean BIS score corresponding to the first word recalled after the procedure was completed was 91.2 (95% CI = 88.1 to 94.3). All patients recalled at least one word that had been read to them during the protocol. The mean lowest BIS score for any recalled word was 91.5 (+/-11.1; range 79 to 98), and no words were recalled when the corresponding BIS score was less than 90. CONCLUSIONS: There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words. Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde \u001b[48;2;173;216;230;38;2;0;0;0mamnesia\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "propofol @CHEMICAL@ amnesia ; inability to repeat words @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "propofol @CHEMICAL@ amnesia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Assessment of perinatal \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m prevention in New Hampshire delivery hospitals. OBJECTIVE: To evaluate current performance on recommended perinatal \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m prevention practices in New Hampshire. METHODS: Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals. Assessment was done on the following: prenatal screening for \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m, administration of the \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m vaccine birth dose to all infants, administration of \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m immune globulin to infants who were born to \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m surface antigen-positive mothers, \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m immunity, and administration of in-hospital postpartum \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m vaccine to \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m nonimmune women. RESULTS: Prenatal screening rates for \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m (98.8%) and \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m (99.4%) were high. \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m vaccine birth dose was administered to 76.2% of all infants. All infants who were born to \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m surface antigen-positive mothers also received \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m immune globulin. Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m vaccination. The proportion of infants who were vaccinated in January and February 2000 (48.5% and 67.5%, respectively) was less than any other months, whereas the proportion who were vaccinated in December 2000 (88.2%) was the highest. Women who were born between 1971 and 1975 had the highest rate of \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m nonimmunity (9.5%). In-hospital postpartum \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m vaccine administration was documented for 75.6% of nonimmune women. CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal \u001b[48;2;173;216;230;38;2;0;0;0mhepatitis b\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mrubella\u001b[00m prevention and highlights potential areas for improvement.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "hepatitis b surface antigen @CHEMICAL@ hepatitis b @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "hepatitis b @CHEMICAL@ rubella @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Mitochondrial DNA and its respiratory chain products are defective in \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m \u001b[48;2;173;216;230;38;2;0;0;0mnephrosis\u001b[00m. BACKGROUND: \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m induces a self-perpetuating \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m characterized by early glomerular and late-onset tubular lesions in rats. We investigated the potential role of mitochondrial injury in the onset of these lesions. METHODS: Rats were treated with intravenous \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose. Additional rats received a single dose either 6 days or 2 h prior to euthanasia. All rats were killed at 48 weeks of age. Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components. Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion. RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity. In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased. In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity. Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes. Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups. CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in \u001b[48;2;173;216;230;38;2;0;0;0mdoxorubicin\u001b[00m-induced renal lesions.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ nephrosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "doxorubicin @CHEMICAL@ nephrosis @DISEASE@ @CID@ doxorubicin @CHEMICAL@ nephropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in a patient with AIDS. OBJECTIVE: To report a case of multiple episodes of \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m activity in an AIDS patent following \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m infusion. CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m during intravenous infusion of \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m, then petit mal \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m persisted and occurred only during \u001b[48;2;144;238;144;38;2;0;0;0mamphotercin b\u001b[00m administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. Didanosine also has a potential for inducing \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. However, these other potential causes of \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m were ruled out. The time course of events suggested that \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m was the cause of the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m in this AIDS patient. CONCLUSIONS: \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m seems to be the probable cause of the \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m. To date, only three cases of \u001b[48;2;173;216;230;38;2;0;0;0mseizures\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0mamphotericin b\u001b[00m have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "amphotericin b ; amphotercin b @CHEMICAL@ seizures ; seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "amphotericin b @CHEMICAL@ seizures ; grand mal seizures @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Therapeutic drug monitoring of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m: once-daily versus twice-daily dosage schedules. OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of \u001b[48;2;144;238;144;38;2;0;0;0mtobramicyn\u001b[00m on steady-state serum concentrations and toxicity. MATERIALS AND METHODS: Patients undergoing treatment with i.v. \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m (4 mg/kg/day) were randomised to two groups. Group OD (n = 22) received a once-daily dose of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m and group TD (n = 21) received the same dose divided into two doses daily. \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m serum concentrations (peak and trough) were measured by enzyme multiplied immunoassay. The renal and auditory functions of the patients were monitored before, during and immediately after treatment. RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function. No statistically significant differences were found in mean daily dose, duration of treatment, or cumulative dose. Trough concentrations were < 2 g/ml in the two groups (100%). Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01). Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01). The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD). Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity. In TD group, three patients developed \u001b[48;2;173;216;230;38;2;0;0;0mdecreased auditory function\u001b[00m, of which one presented with an \u001b[48;2;144;238;144;38;2;0;0;0mauditory loss\u001b[00m of -30 dB, whereas in the OD group only one patient presented \u001b[48;2;173;216;230;38;2;0;0;0mdecreased auditory function\u001b[00m. CONCLUSION: This small study suggests that a once-daily dosing regimen of \u001b[48;2;173;216;230;38;2;0;0;0mtobramycin\u001b[00m is at least as effective as and is no more and possibly less toxic than the twice-daily regimen. Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "tobramycin ; tobramicyn @CHEMICAL@ decreased auditory function ; auditory loss @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "tobramycin @CHEMICAL@ decreased auditory function @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Neuropeptide-Y immunoreactivity in the \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m model of \u001b[48;2;173;216;230;38;2;0;0;0mtemporal lobe epilepsy\u001b[00m. Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental \u001b[48;2;173;216;230;38;2;0;0;0mtemporal lobe epilepsy\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mtle\u001b[00m). This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices. The \u001b[48;2;173;216;230;38;2;0;0;0mpilocarpine\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mpilo\u001b[00m) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage. We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model. \u001b[48;2;144;238;144;38;2;0;0;0mpilo\u001b[00m-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells. NPY immunoreactivity was also dramatically changed in the entorhinal cortex, amygdala and sensorimotor areas. In addition, \u001b[48;2;144;238;144;38;2;0;0;0mpilo\u001b[00m injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls. The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the \u001b[48;2;144;238;144;38;2;0;0;0mpilo\u001b[00m model of \u001b[48;2;173;216;230;38;2;0;0;0mtle\u001b[00m. However, the significance of this changed synthesis of NPY remains to be determined.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "pilocarpine ; pilo @CHEMICAL@ temporal lobe epilepsy ; tle @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "pilocarpine @CHEMICAL@ temporal lobe epilepsy ; tle @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve. PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve. SETTING: Eye Clinic, S. Salvatore Hospital, L'Aquila University, Italy. METHODS: Standard pattern electroretinograms (P-ERGs) and standard pattern visual evoked potentials (P-VEPs) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5.00 and 15.00 diopters (D) (mean 8.00 D). Testing was done preoperatively and 3, 6, 12, and 18 months postoperatively. The contralateral eyes served as controls. During the follow-up, 3 patients (12%) developed \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0melevated intraocular pressure\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m) that resolved after \u001b[48;2;144;238;144;38;2;0;0;0mcorticosteroid\u001b[00m therapy was discontinued. RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively. CONCLUSION: Myopic excimer laser PRK did not seem to affect the posterior segment. The transient \u001b[48;2;173;216;230;38;2;0;0;0msteroid\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0miop\u001b[00m rise did not seem to cause functional impairment.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "corticosteroid @CHEMICAL@ elevated intraocular pressure ; iop rise @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "steroid @CHEMICAL@ elevated intraocular pressure ; iop @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m in advanced Kaposi's sarcoma: a phase II study. We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0mdaunoxome\u001b[00m) in the treatment of AIDS related Kaposi's sarcoma. Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial. Changes in size, colour and associated oedema of selected 'target' lesions were measured. Clinical, biochemical and haematological toxicities were assessed. Ten subjects were evaluated. A partial response was achieved in four, of whom two subsequently relapsed. Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four. The drug was generally well tolerated, with few mild symptoms of toxicity. The main problem encountered was haematological toxicity, with three subjects experiencing severe \u001b[48;2;173;216;230;38;2;0;0;0mneutropenia\u001b[00m (neutrophil count < 0.5 x 10(9)/l). There was no evidence of cardiotoxicity. In this small patient sample, liposomal \u001b[48;2;173;216;230;38;2;0;0;0mdaunorubicin\u001b[00m was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "daunorubicin @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "daunorubicin ; daunoxome @CHEMICAL@ neutropenia @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Failure of ancrod in the treatment of \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;173;216;230;38;2;0;0;0marterial \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m\u001b[00m. The morbidity and mortality associated with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m remain high despite numerous empirical therapies. Ancrod has been used successfully for prophylaxis against development of \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m in patients with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m induced platelet aggregation who require brief reexposure to \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m, but its success in patients who have developed the \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m syndrome is not well defined. The authors present a case of failure of ancrod treatment in a patient with \u001b[48;2;173;216;230;38;2;0;0;0mheparin\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mthrombosis\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "heparin @CHEMICAL@ thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "heparin @CHEMICAL@ arterial thrombosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m after \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m administration in a pediatric patient. \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines. \u001b[48;2;144;238;144;38;2;0;0;0mseizures\u001b[00m and cardiac arrhythmias have complicated its use in adult patients. Overdose patients who have coingested \u001b[48;2;173;216;230;38;2;0;0;0mtricyclic antidepressants\u001b[00m have a higher risk of these complications. Little information exists concerning adverse effects of \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m in children. We report the occurrence of a generalized tonic-clonic \u001b[48;2;173;216;230;38;2;0;0;0mseizure\u001b[00m in a pediatric patient following the administration of \u001b[48;2;173;216;230;38;2;0;0;0mflumazenil\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "flumazenil @CHEMICAL@ seizure ; seizures ; tonic-clonic seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "flumazenil @CHEMICAL@ seizure @DISEASE@ @CID@ tricyclic antidepressants @CHEMICAL@ seizure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Selective injection of \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m into the left coronary artery of the dog. Induction of \u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m and decrease of aortic pressure. In twenty beagle dogs selective injections were made into the left coronary artery with \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m, \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m in doses of 4 ml, 8 ml and 16 ml. Thirty-six \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m injections, 35 \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m injections and 37 \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m injections were made. Frequencies of \u001b[48;2;173;216;230;38;2;0;0;0mventricular fibrillation\u001b[00m were significantly lower (p less than 0.05) after \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m (0%) and \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m (3%) than after \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m (22%). \u001b[48;2;173;216;230;38;2;0;0;0miopentol\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0miohexol\u001b[00m also produced significantly less decrease in aortic blood pressure than \u001b[48;2;173;216;230;38;2;0;0;0mmetrizoate\u001b[00m at the different doses.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "metrizoate @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "iopentol @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ iohexol @CHEMICAL@ ventricular fibrillation @DISEASE@ @CID@ metrizoate @CHEMICAL@ decrease of aortic blood pressure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Magnetic resonance imaging of \u001b[48;2;173;216;230;38;2;0;0;0mcerebral \u001b[48;2;144;238;144;38;2;0;0;0mvenous thrombosis\u001b[00m\u001b[00m secondary to \"low-dose\" \u001b[48;2;173;216;230;38;2;0;0;0mbirth control pills\u001b[00m. The clinical and radiographic features of cerebral \u001b[48;2;144;238;144;38;2;0;0;0mdeep \u001b[48;2;144;238;144;38;2;0;0;0mvenous thrombosis\u001b[00m\u001b[00m in a 21-year-old white woman are presented. This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes. The only known risk factor was \"low-dose\" \u001b[48;2;144;238;144;38;2;0;0;0moral contraceptive\u001b[00m pills. The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus. The diagnosis was confirmed by arterial angiography.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptive @CHEMICAL@ venous thrombosis ; deep venous thrombosis @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "birth control pills @CHEMICAL@ cerebral venous thrombosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary stenosis\u001b[00m: correlation with thallium-201 single-photon emission tomography. It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of \u001b[48;2;144;238;144;38;2;0;0;0mhyperemic\u001b[00m stimulation. The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary stenosis\u001b[00m. The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT). During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced. The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002). During \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mhyperemia\u001b[00m, 12 of the 16 dogs with a partial \u001b[48;2;173;216;230;38;2;0;0;0mcoronary stenosis\u001b[00m had a visible area of hypoperfusion by contrast echocardiography. The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mhyperemia\u001b[00m. The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02). Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during \u001b[48;2;173;216;230;38;2;0;0;0mdipyridamole\u001b[00m-induced \u001b[48;2;144;238;144;38;2;0;0;0mhyperemia\u001b[00m; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03). Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of \u001b[48;2;173;216;230;38;2;0;0;0mcoronary stenosis\u001b[00m. The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium-201 SPECT.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "dipyridamole @CHEMICAL@ hyperemic ; hyperemia @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "dipyridamole @CHEMICAL@ coronary stenosis @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Potential deleterious effect of \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m in radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m. The purpose of the study was to determine the efficacy of \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m in addition to intravenous fluids in the prevention of radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m. 18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital. In addition to fluids, the treatment group received \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material. The control group received fluids (mean 3 liters). Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml. \u001b[48;2;144;238;144;38;2;0;0;0mrenal function significantly deteriorated\u001b[00m in the group pretreated with \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l). Renal failure was associated with weight loss in the \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m-treated group. \u001b[48;2;173;216;230;38;2;0;0;0mfurosemide\u001b[00m may be deleterious in the prevention of radiocontrast \u001b[48;2;173;216;230;38;2;0;0;0mnephropathy\u001b[00m.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "furosemide @CHEMICAL@ renal function significantly deteriorated @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "furosemide @CHEMICAL@ nephropathy @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Etiologic factors in the pathogenesis of \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m associated with \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m. Within the last several years, previously rare \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m have been seen in young women using \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive steroids\u001b[00m. The Registry for \u001b[48;2;173;216;230;38;2;0;0;0mliver tumors\u001b[00m Associated with \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptives\u001b[00m at the University of California, Irvine, has clearly identified 27 cases. The recent literature contains 44 case reports. Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of \u001b[48;2;173;216;230;38;2;0;0;0moral contraceptive steroids\u001b[00m. Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive @CHEMICAL@ liver tumors @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "oral contraceptives ; oral contraceptive steroids @CHEMICAL@ liver tumors ; liver tumors @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Graft-versus-host disease prophylaxis with \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m is associated with a high incidence of \u001b[48;2;173;216;230;38;2;0;0;0msinusoidal obstruction syndrome\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mmicroangiopathy\u001b[00m: results of the EVTAC trial. A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of \u001b[48;2;173;216;230;38;2;0;0;0meverolimus\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mtacrolimus\u001b[00m in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated \u001b[48;2;144;238;144;38;2;0;0;0mmicroangiopathy\u001b[00m (\u001b[48;2;144;238;144;38;2;0;0;0mtma\u001b[00m) occurred in 7 patients (29%), with 2 cases of \u001b[48;2;144;238;144;38;2;0;0;0macute renal failure\u001b[00m. The study was terminated prematurely because an additional 6 patients (25%) developed \u001b[48;2;173;216;230;38;2;0;0;0msinusoidal obstruction syndrome\u001b[00m (\u001b[48;2;173;216;230;38;2;0;0;0msos\u001b[00m), which was fatal in 2 cases. With a median follow-up of 26 months, the 2-year overall survival rate was 47%. Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of \u001b[48;2;144;238;144;38;2;0;0;0mtma\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0msos\u001b[00m is considerably higher than seen with other regimens.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "everolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ everolimus @CHEMICAL@ microangiopathy ; transplantation-associated microangiopathy ; tma @DISEASE@ @CID@ everolimus @CHEMICAL@ acute renal failure @DISEASE@ @CID@ tacrolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ tacrolimus @CHEMICAL@ microangiopathy ; transplantation-associated microangiopathy ; tma @DISEASE@ @CID@ tacrolimus @CHEMICAL@ acute renal failure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "everolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@ tacrolimus @CHEMICAL@ sinusoidal obstruction syndrome ; sos @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "Effect of some convulsants on the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m and its combinations with valproate or clonazepam in amygdala-kindled rats. \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both \u001b[48;2;144;238;144;38;2;0;0;0mseizure\u001b[00m and afterdischarge durations. The combinations of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, \u001b[48;2;144;238;144;38;2;0;0;0mbicuculline\u001b[00m, N-methyl-D-aspartic acid and \u001b[48;2;144;238;144;38;2;0;0;0mbay k-8644\u001b[00m (the opener of L-type calcium channels) reversed the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m alone and its combination with valproate. On the other hand, \u001b[48;2;144;238;144;38;2;0;0;0mbicuculline\u001b[00m, \u001b[48;2;144;238;144;38;2;0;0;0maminophylline\u001b[00m and \u001b[48;2;144;238;144;38;2;0;0;0mbay k-8644\u001b[00m inhibited the anticonvulsive action of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m combined with clonazepam. The results support the hypothesis that the protective activity of \u001b[48;2;173;216;230;38;2;0;0;0mloreclezole\u001b[00m and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bicuculline @CHEMICAL@ seizure @DISEASE@ @CID@ bay k-8644 @CHEMICAL@ seizure @DISEASE@ @CID@ aminophylline @CHEMICAL@ seizure @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "loreclezole @CHEMICAL@ convulsions @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n",
      "\u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m with concurrent \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m therapy. OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m and \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m. CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m and propranolol for the past 5 years. He received a 10-day course of \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m as an aid for smoking cessation 10 weeks prior to presentation. He developed \u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific \u001b[48;2;144;238;144;38;2;0;0;0mdrug-induced acute liver injury\u001b[00m. His condition was further complicated by sepsis and coagulopathy. Death resulted 19 days after the onset of symptoms. The likelihood that \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m induced \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m in our patient was possible, based on the Naranjo probability scale. DISCUSSION: Although there is increasing evidence of \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxicity\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m, this is the first case of fatality that could have resulted from \u001b[48;2;173;216;230;38;2;0;0;0macute liver failure\u001b[00m in a patient receiving \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m while on concomitant treatment with \u001b[48;2;173;216;230;38;2;0;0;0mcarbimazole\u001b[00m. CONCLUSIONS: Clinicians should be aware of the possibility of \u001b[48;2;144;238;144;38;2;0;0;0macute liver insult\u001b[00m induced by \u001b[48;2;173;216;230;38;2;0;0;0mbupropion\u001b[00m given concurrently with other \u001b[48;2;144;238;144;38;2;0;0;0mhepatotoxic\u001b[00m drugs.\n",
      "\u001b[38;5;2m✔ Expected output:\u001b[0m\n",
      "bupropion @CHEMICAL@ acute liver failure ; acute liver insult @DISEASE@ @CID@ bupropion @CHEMICAL@ drug-induced acute liver injury ; hepatotoxicity ; hepatotoxic @DISEASE@ @CID@ carbimazole @CHEMICAL@ acute liver failure ; acute liver insult @DISEASE@ @CID@ carbimazole @CHEMICAL@ drug-induced acute liver injury ; hepatotoxicity ; hepatotoxic @DISEASE@ @CID@\n",
      "\u001b[38;5;4mℹ Actual output:\u001b[0m\n",
      "bupropion @CHEMICAL@ acute liver failure @DISEASE@ @CID@ carbimazole @CHEMICAL@ acute liver failure @DISEASE@ @CID@\n",
      "\n",
      "\n",
      "\n",
      "\u001b[38;5;4mℹ input text\u001b[0m\n"
     ]
    },
    {
     "ename": "ValueError",
     "evalue": "Text is unstructured: 'oestrogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ dementia @DISEASE@ @CID@ progestogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ breast cancer @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ breast cancer @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @'\nText should end with a relationship label found in re_labels: ['@CID@'].\n",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[28], line 5\u001b[0m\n\u001b[1;32m      3\u001b[0m msg\u001b[38;5;241m.\u001b[39minfo(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124minput text\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m      4\u001b[0m rels_expected\u001b[38;5;241m=\u001b[39mextract_relation_triples(row[\u001b[38;5;241m1\u001b[39m][\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mexpected output\u001b[39m\u001b[38;5;124m\"\u001b[39m], config[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mner_labels\u001b[39m\u001b[38;5;124m\"\u001b[39m], config[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mre_labels\u001b[39m\u001b[38;5;124m\"\u001b[39m], \u001b[38;5;28;01mTrue\u001b[39;00m)\n\u001b[0;32m----> 5\u001b[0m rels_predicted\u001b[38;5;241m=\u001b[39m\u001b[43mextract_relation_triples\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrow\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpredicted output\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mner_labels\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mre_labels\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m)\u001b[49m\n\u001b[1;32m      6\u001b[0m \u001b[38;5;28mprint\u001b[39m(highlight_entities(row[\u001b[38;5;241m1\u001b[39m][\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124minput\u001b[39m\u001b[38;5;124m\"\u001b[39m], rels_expected, rels_predicted))\n\u001b[1;32m      7\u001b[0m msg\u001b[38;5;241m.\u001b[39mgood(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mExpected output:\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/Generative-re-tests/notebooks/helper_functions.py:48\u001b[0m, in \u001b[0;36mextract_relation_triples\u001b[0;34m(text, ner_labels, re_labels, keep_coreforents)\u001b[0m\n\u001b[1;32m     46\u001b[0m \u001b[38;5;66;03m# check if text ends with a relation label\u001b[39;00m\n\u001b[1;32m     47\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m split_on_space_text[\u001b[38;5;241m-\u001b[39m\u001b[38;5;241m1\u001b[39m] \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m re_labels:\n\u001b[0;32m---> 48\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mText is unstructured: \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mtext\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m'\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124mText should end with a relationship label found in re_labels: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mre_labels\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m     50\u001b[0m \u001b[38;5;66;03m# Check if text has atleast two entity labels and one relation label\u001b[39;00m\n\u001b[1;32m     51\u001b[0m count_ner_labels \u001b[38;5;241m=\u001b[39m \u001b[38;5;28msum\u001b[39m([split_on_space_text\u001b[38;5;241m.\u001b[39mcount(label) \u001b[38;5;28;01mfor\u001b[39;00m label \u001b[38;5;129;01min\u001b[39;00m ner_labels])\n",
      "\u001b[0;31mValueError\u001b[0m: Text is unstructured: 'oestrogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ dementia @DISEASE@ @CID@ progestogens @CHEMICAL@ venous thrombo-embolism @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ breast cancer @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ breast cancer @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @CHEMICAL@ stroke @DISEASE@ @CID@ progestogens @'\nText should end with a relationship label found in re_labels: ['@CID@'].\n"
     ]
    }
   ],
   "source": [
    "print(\"Entities of expected output colored \\033[48;2;144;238;144;38;2;0;0;0mgreen\\033[00m, of predicted \\033[48;2;173;216;230;38;2;0;0;0mblue\\033[00m\\n\")\n",
    "for row in dataframe[dataframe[\"match\"]==False].iterrows():\n",
    "    msg.info(\"input text\")\n",
    "    rels_expected=extract_relation_triples(row[1][\"expected output\"], config[\"ner_labels\"], config[\"re_labels\"], True)\n",
    "    rels_predicted=extract_relation_triples(row[1][\"predicted output\"], config[\"ner_labels\"], config[\"re_labels\"], True)\n",
    "    print(highlight_entities(row[1][\"input\"], rels_expected, rels_predicted))\n",
    "    msg.good(\"Expected output:\")\n",
    "    print(row[1][\"expected output\"])\n",
    "    msg.info(\"Actual output:\")\n",
    "    print(row[1][\"predicted output\"])\n",
    "    print(\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f1470779-494a-41f5-a227-0f05cfeaabc1",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "gen_re",
   "language": "python",
   "name": "gen_re"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
